Results 251 to 260 of about 127,319 (303)
Some of the next articles are maybe not open access.
Hepatitis B Vaccine in a Hospital
Annals of Internal Medicine, 1984Excerpt To the editor: In their recent article, Dienstag and associates (1) report a high level of immune response in hospital personnel to hepatitis B vaccine.
D M, Schaaff +3 more
openaire +2 more sources
Journal of Hepatology, 2003
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +2 more sources
Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults. Newly developed pre-S/S hepatitis B vaccines may play a role in inducing fast and augmented seroconversion rates in special risk groups.
openaire +2 more sources
American Journal of Gastroenterology, 2013
To the Editor: We read with great interest the article by Gisbert et al. (1), which investigated giving vaccine against hepatitis B virus (HBV) at an accelerated, double dosage in patients with inflammatory bowel disease (IBD). The overall seroconversion rate was low, particularly in those receiving biological therapy.
Jeanne, Tung +3 more
openaire +2 more sources
To the Editor: We read with great interest the article by Gisbert et al. (1), which investigated giving vaccine against hepatitis B virus (HBV) at an accelerated, double dosage in patients with inflammatory bowel disease (IBD). The overall seroconversion rate was low, particularly in those receiving biological therapy.
Jeanne, Tung +3 more
openaire +2 more sources
Hepatitis B Vaccination Safety
Annals of Pharmacotherapy, 2002BACKGROUND: Recent studies have suggested that adult hepatitis B vaccination may be associated with adverse reactions. OBJECTIVE: To further examine the relative risk, percentage association, and statistical significance of arthritic, immunologic, and gastrointestinal adverse reactions reported after adult hepatitis B vaccination compared with control ...
Mark R, Geier, David A, Geier
openaire +2 more sources
Journal of Infection, 1986
Development of vaccines against hepatitis B has proceeded along four main lines. Human plasma-derived vaccines are safe, effective, and in general use. Subunit polypeptide vaccines formulated in micelles have reached the stage of clinical trials. Recombinant DNA vaccines have been produced in prokaryotic and eukaryotic cells, notably in yeast.
openaire +2 more sources
Development of vaccines against hepatitis B has proceeded along four main lines. Human plasma-derived vaccines are safe, effective, and in general use. Subunit polypeptide vaccines formulated in micelles have reached the stage of clinical trials. Recombinant DNA vaccines have been produced in prokaryotic and eukaryotic cells, notably in yeast.
openaire +2 more sources
Hepatitis B Vaccination for Ophthalmologists
Archives of Ophthalmology, 1987To the Editor. —In response to Dr Reinecke's1excellent article concerning the safety and benefits of the hepatitis B vaccine I would add two points. First, if the general safety of the vaccine is inadequate to assuage ardent skeptics, then one can check their vaccine lot number to see if it was tested for human immunodeficiency virus by the American ...
openaire +2 more sources
A review of hepatitis B vaccination
Expert Opinion on Drug Safety, 2003Hepatitis B is one of the most important infectious causes of acute and chronic liver disease both in the US and worldwide. In order to combat the life-threatening effects of hepatitis B infection, recombinant hepatitis B vaccines have been developed.
Mark R, Geier +2 more
openaire +2 more sources
The Nurse Practitioner, 1983
Hepatitis B is a major public health problem. Complications of the disease can include a carrier state, chronic active hepatitis, cirrhosis and hepatocellular carcinoma. The development of hepatitis B virus vaccine has made active immunization against HBV possible.
openaire +2 more sources
Hepatitis B is a major public health problem. Complications of the disease can include a carrier state, chronic active hepatitis, cirrhosis and hepatocellular carcinoma. The development of hepatitis B virus vaccine has made active immunization against HBV possible.
openaire +2 more sources
2017
Hepatitis A is a liver disease caused by the hepatitis A virus (HAV). The incubation period of hepatitis A is usually 14–28 days. Symptoms of hepatitis A range from mild to severe, and can include fever, malaise, loss of appetite, diarrhea, nausea, abdominal discomfort, dark-colored urine, and jaundice (a yellowing of the skin and whites of the eyes ...
openaire +1 more source
Hepatitis A is a liver disease caused by the hepatitis A virus (HAV). The incubation period of hepatitis A is usually 14–28 days. Symptoms of hepatitis A range from mild to severe, and can include fever, malaise, loss of appetite, diarrhea, nausea, abdominal discomfort, dark-colored urine, and jaundice (a yellowing of the skin and whites of the eyes ...
openaire +1 more source
Experience with hepatitis B vaccine
Medical Journal of Australia, 1986Christopher J ...
openaire +3 more sources